The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression

Grégory Aubert, Virginie Mansuy, Marie Jeanne Voirol, Luc Pellerin, François P. Pralong

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Metformin demonstrates anorectic effects in vivo and inhibits neuropeptide Y expression in cultured hypothalamic neurons. Here we investigated the mechanisms implicated in the modulation of feeding by metformin in animals rendered obese by long-term high-fat diet (diet-induced obesity [DIO]) and in animals resistant to obesity (diet resistant [DR]). Male Long-Evans rats were kept on normal chow feeding (controls) or on high-fat diet (DIO, DR) for 6 months. Afterward, rats were treated 14 days with metformin (75 mg/kg) or isotonic sodium chloride solution and killed. Energy efficiency, metabolic parameters, and gene expression were analyzed at the end of the high-fat diet period and after 14 days of metformin treatment. At the end of the high-fat diet period, despite higher leptin levels, DIO rats had higher levels of hypothalamic neuropeptide Y expression than DR or control rats, suggesting a central leptin resistance. In DIO but also in DR rats, metformin treatment induced significant reductions of food intake accompanied by decreases in body weight. Interestingly, the weight loss achieved by metformin was correlated with pretreatment plasma leptin levels. This effect was paralleled by a stimulation of the expression of the leptin receptor gene (ObRb) in the arcuate nucleus. These data identify the hypothalamic ObRb as a gene modulated after metformin treatment and suggest that the anorectic effects of the drug are potentially mediated via an increase in the central sensitivity to leptin. Thus, they provide a rationale for novel therapeutic approaches associating leptin and metformin in the treatment of obesity.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume60
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Leptin Receptors
Metformin
Diet
Leptin
Obesity
High Fat Diet
Appetite Depressants
Neuropeptide Y
Long Evans Rats
Arcuate Nucleus of Hypothalamus
Sodium Chloride
Genes
Weight Loss
Eating
Body Weight
Gene Expression
Neurons

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. / Aubert, Grégory; Mansuy, Virginie; Voirol, Marie Jeanne; Pellerin, Luc; Pralong, François P.

In: Metabolism: Clinical and Experimental, Vol. 60, No. 3, 03.2011, p. 327-334.

Research output: Contribution to journalArticle

Aubert, Grégory ; Mansuy, Virginie ; Voirol, Marie Jeanne ; Pellerin, Luc ; Pralong, François P. / The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. In: Metabolism: Clinical and Experimental. 2011 ; Vol. 60, No. 3. pp. 327-334.
@article{df98b6326a684a71a76442ffb2121c44,
title = "The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression",
abstract = "Metformin demonstrates anorectic effects in vivo and inhibits neuropeptide Y expression in cultured hypothalamic neurons. Here we investigated the mechanisms implicated in the modulation of feeding by metformin in animals rendered obese by long-term high-fat diet (diet-induced obesity [DIO]) and in animals resistant to obesity (diet resistant [DR]). Male Long-Evans rats were kept on normal chow feeding (controls) or on high-fat diet (DIO, DR) for 6 months. Afterward, rats were treated 14 days with metformin (75 mg/kg) or isotonic sodium chloride solution and killed. Energy efficiency, metabolic parameters, and gene expression were analyzed at the end of the high-fat diet period and after 14 days of metformin treatment. At the end of the high-fat diet period, despite higher leptin levels, DIO rats had higher levels of hypothalamic neuropeptide Y expression than DR or control rats, suggesting a central leptin resistance. In DIO but also in DR rats, metformin treatment induced significant reductions of food intake accompanied by decreases in body weight. Interestingly, the weight loss achieved by metformin was correlated with pretreatment plasma leptin levels. This effect was paralleled by a stimulation of the expression of the leptin receptor gene (ObRb) in the arcuate nucleus. These data identify the hypothalamic ObRb as a gene modulated after metformin treatment and suggest that the anorectic effects of the drug are potentially mediated via an increase in the central sensitivity to leptin. Thus, they provide a rationale for novel therapeutic approaches associating leptin and metformin in the treatment of obesity.",
author = "Gr{\'e}gory Aubert and Virginie Mansuy and Voirol, {Marie Jeanne} and Luc Pellerin and Pralong, {Fran{\cc}ois P.}",
year = "2011",
month = "3",
doi = "10.1016/j.metabol.2010.02.007",
language = "English (US)",
volume = "60",
pages = "327--334",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression

AU - Aubert, Grégory

AU - Mansuy, Virginie

AU - Voirol, Marie Jeanne

AU - Pellerin, Luc

AU - Pralong, François P.

PY - 2011/3

Y1 - 2011/3

N2 - Metformin demonstrates anorectic effects in vivo and inhibits neuropeptide Y expression in cultured hypothalamic neurons. Here we investigated the mechanisms implicated in the modulation of feeding by metformin in animals rendered obese by long-term high-fat diet (diet-induced obesity [DIO]) and in animals resistant to obesity (diet resistant [DR]). Male Long-Evans rats were kept on normal chow feeding (controls) or on high-fat diet (DIO, DR) for 6 months. Afterward, rats were treated 14 days with metformin (75 mg/kg) or isotonic sodium chloride solution and killed. Energy efficiency, metabolic parameters, and gene expression were analyzed at the end of the high-fat diet period and after 14 days of metformin treatment. At the end of the high-fat diet period, despite higher leptin levels, DIO rats had higher levels of hypothalamic neuropeptide Y expression than DR or control rats, suggesting a central leptin resistance. In DIO but also in DR rats, metformin treatment induced significant reductions of food intake accompanied by decreases in body weight. Interestingly, the weight loss achieved by metformin was correlated with pretreatment plasma leptin levels. This effect was paralleled by a stimulation of the expression of the leptin receptor gene (ObRb) in the arcuate nucleus. These data identify the hypothalamic ObRb as a gene modulated after metformin treatment and suggest that the anorectic effects of the drug are potentially mediated via an increase in the central sensitivity to leptin. Thus, they provide a rationale for novel therapeutic approaches associating leptin and metformin in the treatment of obesity.

AB - Metformin demonstrates anorectic effects in vivo and inhibits neuropeptide Y expression in cultured hypothalamic neurons. Here we investigated the mechanisms implicated in the modulation of feeding by metformin in animals rendered obese by long-term high-fat diet (diet-induced obesity [DIO]) and in animals resistant to obesity (diet resistant [DR]). Male Long-Evans rats were kept on normal chow feeding (controls) or on high-fat diet (DIO, DR) for 6 months. Afterward, rats were treated 14 days with metformin (75 mg/kg) or isotonic sodium chloride solution and killed. Energy efficiency, metabolic parameters, and gene expression were analyzed at the end of the high-fat diet period and after 14 days of metformin treatment. At the end of the high-fat diet period, despite higher leptin levels, DIO rats had higher levels of hypothalamic neuropeptide Y expression than DR or control rats, suggesting a central leptin resistance. In DIO but also in DR rats, metformin treatment induced significant reductions of food intake accompanied by decreases in body weight. Interestingly, the weight loss achieved by metformin was correlated with pretreatment plasma leptin levels. This effect was paralleled by a stimulation of the expression of the leptin receptor gene (ObRb) in the arcuate nucleus. These data identify the hypothalamic ObRb as a gene modulated after metformin treatment and suggest that the anorectic effects of the drug are potentially mediated via an increase in the central sensitivity to leptin. Thus, they provide a rationale for novel therapeutic approaches associating leptin and metformin in the treatment of obesity.

UR - http://www.scopus.com/inward/record.url?scp=79951783938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951783938&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2010.02.007

DO - 10.1016/j.metabol.2010.02.007

M3 - Article

C2 - 20303124

AN - SCOPUS:79951783938

VL - 60

SP - 327

EP - 334

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 3

ER -